Physician profile
Daniel A Skora
NPI 1750609376
$3,473.37
in general payments reported to CMS, 2019-2025
13 companies · $679 in 2025
The $679 reported for 2025 was more than what 90% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $205 · 2021: $630 · 2022: $553 · 2023: $629 · 2024: $465 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,682.54 | 2019-2025 | Menopur |
| Coopersurgical, INC. | $587.10 | 2021-2025 | Stripper |
| Emd Serono, INC. | $381.67 | 2019-2024 | |
| Organon LLC | $243.30 | 2022-2025 | Follistim Aq, Pregnyl, Ganirelix Acetate |
| Vitrolife INC. | $236.73 | 2022 | |
| Abbvie INC. | $98.24 | 2021 | |
| Hologic Sales and Service, LLC | $77.70 | 2019-2025 | Aptima |
| Myriad Women'S Health, INC. | $56.00 | 2023 | Genesight |
| Merck Sharp & Dohme LLC | $33.20 | 2020-2021 | |
| Novo Nordisk INC | $31.39 | 2025 | Wegovy |
| Meditrina | $21.72 | 2025 | |
| Myovant Sciences INC. | $12.87 | 2021 | |
| Galen US INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Skora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.